Back to search
FDAFDA · Food and drugs·Recall number Z-1686-2016

Diamedix Is-EBV-VCA IgG Test Kit Diamedix Is-Mumps IgG Test Kit is an EIA procedure intended for the qualitative and semi-quantitative detection of Mumps IgG antibodies as an aid in the diagnosis of Mumps infection.

Published May 25, 2016 · Recall initiated: October 20, 2014

Summary

FDA records medical device Class II recall Z-1686-2016, published May 25, 2016 and initiated October 20, 2014. Recalling firm: Diamedix Corporation; Status: Terminated; Reported quantity: 588 kits; Lot: Lot # 30804, Catalog # 720-600 Expiration Date April 30, 2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

A gel-like substance was found in kit component, sample diluent , that could potentially compromise product performance.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Diamedix Corporation
Distributor
Worldwide distribution: US nationwide including states of: AZ, CA, CO, FL, GA, IL, IN, KY, MA, MI, MO, NC, NE, NH, NJ, NY, OH, OK, OR, PA, RI, TN, TX, VA, WI and Puerto Rico. and Country of: ITALY.
Lot
Lot # 30804, Catalog # 720-600 Expiration Date April 30, 2015
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Diamedix Is-EBV-VCA IgG Test Kit Diamedix Is-Mumps IgG Test Kit is an EIA procedure intended for the qualitative and semi-quantitative detection of Mumps IgG antibodies as an aid in the diagnosis of Mumps infection. recalled?

Yes. FDA published recall Z-1686-2016 on May 25, 2016. Reported hazard: A gel-like substance was found in kit component, sample diluent , that could potentially compromise product performance.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit